Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

169.95
-4.8100-2.75%
Post-market: 168.00-1.9500-1.15%19:53 EST
Volume:1.07M
Turnover:181.15M
Market Cap:8.69B
PE:-46.18
High:175.30
Open:175.01
Low:166.88
Close:174.76
52wk High:191.50
52wk Low:86.99
Shares:51.15M
Float Shares:41.87M
Volume Ratio:1.84
T/O Rate:2.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6800
EPS(LYR):-3.6821
ROE:-252.11%
ROA:-16.81%
PB:98.46
PE(LYR):-46.16

Loading ...

BRIEF-Axsome Therapeutics Q4 Net Income USD -28.559 Million

Reuters
·
Feb 23

Axsome Therapeutics Q4 EPS USD -0.56

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Q4 Pretax Profit USD -28.129 Million

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Q4 Revenue USD 195.999 Million VS. Ibes Estimate USD 193.1 Million

THOMSON REUTERS
·
Feb 23

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Feb 23

Mizuho Adjusts Price Target on Axsome Therapeutics to $230 From $217, Maintains Outperform Rating

MT Newswires Live
·
Feb 19

Analysts Are Bullish on These Healthcare Stocks: Demant (WILLF), Axsome Therapeutics (AXSM)

TIPRANKS
·
Feb 19

Axsome Therapeutics: Strengthened Sunosi Exclusivity and Robust Late‑Stage Pipeline Underpin Buy Rating

TIPRANKS
·
Feb 18

BRIEF-Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Alkem Laboratories Ltd.

Reuters
·
Feb 17

Axsome Therapeutics Settles SUNOSI Patent Litigation with Alkem

Reuters
·
Feb 17

Axsome Therapeutics Inc - Patent Litigation Against Another Party Related to Sunosi Pending

THOMSON REUTERS
·
Feb 17

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

GlobeNewswire
·
Feb 17

Earning Preview: Axsome Therapeutics Q4 revenue is expected to increase by 63.74%, and institutional views are bullish

Earnings Agent
·
Feb 16

Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)

Simply Wall St.
·
Feb 06

Axsome Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 03

U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp

Reuters
·
Feb 03

Axsome Therapeutics CEO Herriot Tabuteau Reports Disposal of Common Shares

Reuters
·
Feb 03

Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says

MT Newswires Live
·
Feb 03

Axsome Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jan 29

Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway

Simply Wall St.
·
Jan 28